Surgical correction of craniosynostosis can involve significant blood loss. Rates of allogenic blood transfusion have been reported to approach 100%. Multiple interventions have been described to reduce blood loss and transfusion requirements. The aim of this study was to analyze various approaches over the last 4 decades to optimize blood loss and management during craniosynostosis surgery.
Design
PRISMA guidelines for systematic reviews were followed. PubMed and Cochrane database searches identified studies analyzing approaches to minimizing blood loss or transfusion rate in craniosynostosis surgery.
Main Outcome Measures
Primary outcomes included rate or amount of allogenic or autologous blood transfusion, estimated blood loss (EBL), postoperative hemoglobin (Hg), or hematocrit (Hct) levels. Secondary outcomes were examined when reported.
Results
Fifty-two studies met inclusion criteria. There was marked heterogeneity regarding design, inclusion criteria, surgical intervention, and endpoints. The majority of the studies were nonrandomized and noncomparative. Four studies analyzed erythropoietin (EPO), 6 analyzed various cell-saver (CS) technologies, 18 analyzed antifibrinolytics (tranexamic acid [TXA], aminocaproic acid [ACA], and aprotinin [APO]), 8 analyzed various alternatives, and 16 analyzed multimodal pathways & protocols. Some studies analyzed multiple approaches.
Conclusions
Although the majority of studies reviewed represent level III/IV evidence, several high-quality level I studies were identified and included. Level I evidence supported an improvement in blood outcomes by utilizing EPO, CS, and TXA, individually or in concert with one another. Thus, this review suggests that a multi-prong approach may be the most effective means to optimize blood loss and transfusion outcomes in craniosynostosis surgery.
CohenMMJr.,. Craniosynostosis and syndromes with craniosynostosis: incidence, genetics, penetrance, variability, and new syndrome updating. Birth Defects Orig Artic Ser. 1979;15(5B):13‐63.
5.
MarchacDRenierDBroumandS. Timing of treatment for craniosynostosis and facio-craniosynostosis: a 20-year experience. Br J Plast Surg. 1994;47(4):211‐222.
6.
KeshavarziS, Hayden MG, Ben-Haim S, Meltzer HS, Cohen SR, Levy ML. Variations of endoscopic and open repair of metopic craniosynostosis. J Craniofac Surg. 2009;20(5):1439‐1444.
7.
MeyerPRenierDArnaudE. Intraoperative autologous blood transfusion in the surgical correction of craniosynostosis. Neurosurgery. 1996;39(1):213.
8.
WhiteN, Marcus R,Dover S, Solanki G, Nishikawa H, Millar C, Carver ED. Predictors of blood loss in fronto-orbital advancement and remodeling. J Craniofac Surg. 2009;20(2):378‐381.
9.
MeyerP, Renier D, Arnaud E, Jarreau MM, Charron B, Buy E, Buisson C, Barrier G. Blood loss during repair of craniosynostosis. Br J Anaesth. 1993;71(6):854‐857.
10.
NatghianH, Song M, Jayamohan J, Johnson D, Magdum S, Richards P, Wall S. Long-Term results in isolated metopic synostosis: the Oxford experience over 22 years. Plast Reconstr Surg. 2018;142(4):509e‐515e.
11.
BirgfeldCB, Dufton L, Naumann H, Hopper RA, Gruss JS, Haberkern CM, Speltz ML. Safety of open cranial vault surgery for single-suture craniosynostosis: a case for the multidisciplinary team. J Craniofac Surg. 2015;26(7):2052‐2058.
12.
OppenheimerAJ, Ranganathan K, Levi B, Strahle JM, Kapurch J, Muraszko KM, Buchman SR. Minimizing transfusions in primary cranial vault remodeling: the role of aminocaproic acid. J Craniofac Surg. 2014;25(1):82‐86.
13.
NguyenTTLamHVPhillipsMEdwardsCAustinTM. Intraoperative optimization to decrease postoperative PRBC transfusion in children undergoing craniofacial reconstruction. Paediatr Anaesth. 2015;25(3):294‐300.
14.
KucukATumturkAGerginISOralSGorkemSBKurtsoyAMadenogluHOktemIS. The management of blood loss in non-syndromic craniosynostosis patients undergoing barrel stave osteotomy. Turk Neurosurg. 2017;27(1):138‐141.
15.
JimenezDFBaroneCM. Intraoperative autologous blood transfusion in the surgical correction of craniosynostosis. Neurosurgery. 1995;37(6):1075‐1079.
16.
AlbrightALPollackIFAdelsonPDSolotJJ. Outcome data and analysis in pediatric neurosurgery. Neurosurgery. 1999;45(1):101‐106.
17.
CzerwinskiMHopperRAGrussJFearonJA. Major morbidity and mortality rates in craniofacial surgery: an analysis of 8101 major procedures. Plast Reconstr Surg. 2010;126(1):181‐186.
18.
VamvakasEC. Long-term survival rate of pediatric patients after blood transfusion. Transfusion. 2008;48(11):2478‐2480.
19.
FaberowskiLWBlackSMickleJP. Blood loss and transfusion practice in the perioperative management of craniosynostosis repair. J Neurosurg Anesthesiol. 1999;11(3):167‐172.
20.
KohJLGriesH. Perioperative management of pediatric patients with craniosynostosis. Anesthesiol Clin. 2007;25(3):465‐481. viii.
21.
PhillipsRJMullikenJB. Venous air embolism during a craniofacial procedure. Plast Reconstr Surg. 1988;82(1):155‐159.
22.
StrickerPA, Shaw TL, Desouza DG, Hernandez SV, Bartlett SP, Friedman DF, Sesok-Pizzini DA, Jobes DR. Blood loss, replacement, and associated morbidity in infants and children undergoing craniofacial surgery. Paediatr Anaesth. 2010;20(2):150‐159.
23.
BurnsPBRohrichRJChungKC. The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg. 2011;128(1):305‐310.
24.
HelfaerMACarsonBSJamesCSGatesJDella-LanaDVander KolkC. Increased hematocrit and decreased transfusion requirements in children given erythropoietin before undergoing craniofacial surgery. J Neurosurg. 1998;88(4):704‐708.
25.
MearaJG, Smith EM, Harshbarger RJ, Farlo JN, Matar MM, Levy ML. Blood-conservation techniques in craniofacial surgery. Ann Plast Surg. 2005;54(5):525‐529.
26.
MeneghiniL, Zadra N, Aneloni V, Metrangolo S, Faggin R, Giusti F. Erythropoietin therapy and acute preoperative normovolaemic haemodilution in infants undergoing craniosynostosis surgery. Paediatr Anaesth. 2003;13(5):392‐396.
27.
FearonJAWeinthalJ. The use of recombinant erythropoietin in the reduction of blood transfusion rates in craniosynostosis repair in infants and children. Plast Reconstr Surg. 2002;109(7):2190‐2196.
28.
DahmaniS, Orliaguet GA, Meyer PG, Blanot S, Renier D, Carli PA. Perioperative blood salvage during surgical correction of craniosynostosis in infants. Br J Anaesth. 2000;85(4):550‐555.
29.
DevaAK, Hopper RA, Landecker A, Flores R, Weiner H, McCarthy JG. The use of intraoperative autotransfusion during cranial vault remodeling for craniosynostosis. Plast Reconstr Surg. 2002;109(1):58‐63.
30.
DuncanC, Richardson D, May P, Thiruchelvam J, Shong DC, Potter F, Grogan J, Caswell M. Reducing blood loss in synostosis surgery: the liverpool experience. J Craniofac Surg. 2008;19(5):1424‐1430.
31.
OrliaguetGA, Bruyere M, Meyer PG, Blanot S, Renier D, Carli PA. Comparison of perioperative blood salvage and postoperative reinfusion of drained blood during surgical correction of craniosynostosis in infants. Paediatr Anaesth. 2003;13(9):797‐804.
32.
FearonJA. Reducing allogenic blood transfusions during pediatric cranial vault surgical procedures: a prospective analysis of blood recycling. Plast Reconstr Surg. 2004;113(4):1126‐1130.
33.
CrantfordJC, Wood BC, Claiborne JR, Ririe DG, Couture DE, Thompson JT, David LR. Evaluating the safety and efficacy of tranexamic acid administration in pediatric cranial vault reconstruction. J Craniofac Surg. 2015;26(1):104‐107.
34.
EngelMBodemJPBuschCJHornDMertensCHoffmannJFreudlspergerC. The value of tranexamic acid during fronto-orbital advancement in isolated metopic craniosynostosis. J Craniomaxillofac Surg. 2015;43(7):1239‐1243.
35.
MartinDTGriesHEsmondeNDiggsBKohJSeldenNRSchreiberMKuangAA. Implementation of a tranexamic acid protocol to reduce blood loss during cranial vault remodeling for craniosynostosis. J Craniofac Surg. 2016;27(6):1527‐1531.
36.
MaugansTAMartinDTaylorJSalisburySIstaphanousG. Comparative analysis of tranexamic acid use in minimally invasive versus open craniosynostosis procedures. J Craniofac Surg. 2011;22(5):1772‐1778.
37.
ReddySKSwinkJMRogersGFMyserosJSKeatingRFSantosDN. Transfusion-Free calvarial vault reconstruction using multimodal blood conservation strategies in two pediatric jehovah’s witness patients with craniosynostosis. A A Case Rep. 2016;7(2):33‐36.
38.
DadureCSauterMBringuierSBigorreMRauxORochetteACanaudNCapdevilaX. Intraoperative tranexamic acid reduces blood transfusion in children undergoing craniosynostosis surgery: a randomized double-blind study. Anesthesiology. 2011;114(4):856‐861.
39.
GoobieSMMeierPMPereiraLMMcGowanFXPrescillaRPScharpLARogersGFProctorMRMearaJGSorianoSGZurakowskiD. Efficacy of tranexamic acid in pediatric craniosynostosis surgery: a double-blind, placebo-controlled trial. Anesthesiology. 2011;114(4):862‐871.
40.
D’ErricoCCMunroHMBuchmanSRWagnerDMuraszkoKM. Efficacy of aprotinin in children undergoing craniofacial surgery. J Neurosurg. 2003;99(2):287‐290.
41.
ThompsonMESaadehCWatkinsPNagyLDemkeJ. Blood loss and transfusion requirements with epsilon-aminocaproic acid use during cranial vault reconstruction surgery. J Clin Anesth. 2017;36:153‐157.
42.
HansenJKLydickAMWyattMMAndrewsBT. Reducing postoperative bleeding after craniosynostosis repair utilizing a low-dose transexamic acid infusion protocol. J Craniofac Surg. 2017;28(5):1255‐1259.
43.
KurnikNMPflibsenLRBristolRESinghDJ. Tranexamic acid reduces blood loss in craniosynostosis surgery. J Craniofac Surg. 2017;28(5):1325‐1329.
44.
NguyenTTLamHVAustinTMStrickerPTuncerogluHSchoeneckerJ. Comparison of different dosage regimes of epsilon aminocaproic acid on blood loss in children undergoing craniosynostosis surgery. Paediatr Anaesth. 2019;29(8):858‐864.
45.
KurnikNMPflibsenLRDoABristolRSinghDJ. Craniosynostosis surgery and the impact of tranexamic acid dosing. J Craniofac Surg. 2018;29(1):96‐98.
46.
Fenger-EriksenCD’Amore LindholmANørholtSE, et al.Reduced perioperative blood loss in children undergoing craniosynostosis surgery using prolonged tranexamic acid infusion: a randomised trial. Br J Anaesth. 2019;122(6):760‐766.
47.
OngunEADursunOKazanMS. Tranexamic acid utilization in craniosynostosis surgery. Turk Neurosurg. 2020;30(3):407‐415.
48.
GoobieSMStaffaSJMearaJGProctorMRTumoloMCangemiGDismaN. High-dose versus low-dose tranexamic acid for paediatric craniosynostosis surgery: a double-blind randomised controlled non-inferiority trial. Br J Anaesth. 2020;125(3):336‐345.
49.
BorstAJBonfieldCMDeenadayalanPSLeCHXuMSobeyJHReddySK. ε-Aminocaproic acid versus tranexamic acid in children undergoing complex cranial vault reconstruction for repair of craniosynostosis. Pediatr Blood Cancer. 2021;68(8):e29093.
50.
HansPCollinVBonhommeVDamasFBornJBLamyM. Evaluation of acute normovolemic hemodilution for surgical repair of craniosynostosis. J Neurosurg Anesthesiol. 2000;12(1):33‐36.
51.
FearonJACookTKHerbertM. Effects of hypotensive anesthesia on blood transfusion rates in craniosynostosis corrections. Plast Reconstr Surg. 2014;133(5):1133‐1136.
52.
LongattiPLPaccagnellaFAgostiniSNieriACarteriA. Autologous hemodonation in the corrective surgery of craniostenosis. Childs Nerv Syst. 1991;7(1):40‐42.
53.
StehrerRHungerSSchottenK-JParsaeiBMalekMJacobMGeiselsederGMeierJ. Reduction of transfusion requirements in pediatric craniosynostosis surgery by a new local hemostatic agent. J Craniomaxillofac Surg. 2016;44(9):1246‐1251.
54.
WhiteNCarverEDRodriguesDDoverSMagdumSNishikawaHSolankiG. Calvarial remodelling for sagittal synostosis: does fibrin glue (tisseel) reduce post-operative blood transfusion requirements?Childs Nerv Syst. 2009;25(7):867‐869.
55.
MachottaAHuismanEJAppelIMLuijnenburgSELopez-YurdaMCnossenMHvan OmmenCH. Prophylactic fibrinogen concentrate administration in surgical correction of paediatric craniosynostosis: a double-blind placebo-controlled trial. Eur J Anaesthesiol. 2021;38(9):908‐915.
56.
HarroudAWeilAGTurgeonJMercierCCrevierL. Association of postoperative furosemide use with a reduced blood transfusion rate in sagittal craniosynostosis surgery. J Neurosurg Pediatr. 2016;17(1):34‐40.
57.
StrickerPAFiadjoeJEKilbaughTJPruittEYTaylorJABartlettSPMcCloskeyJJ. Effect of transfusion guidelines on postoperative transfusion in children undergoing craniofacial reconstruction surgery. Pediatr Crit Care Med. 2012;13(6):e357‐e362.
58.
KrajewskiKAshleyRKPungNWaldSLazareffJKawamotoHKBradleyJP. Successful blood conservation during craniosynostotic correction with dual therapy using procrit and cell saver. J Craniofac Surg. 2008;19(1):101‐105.
59.
NguyenTTHillSAustinTMWhitneyGMWellonsJcLamHV. Use of blood-sparing surgical techniques and transfusion algorithms: association with decreased blood administration in children undergoing primary open craniosynostosis repair. J Neurosurg Pediatr. 2015;16(5):556‐563.
60.
HaasTGoobieSSpielmannNWeissMSchmuggeM. Improvements in patient blood management for pediatric craniosynostosis surgery using a ROTEM((R))-assisted strategy—feasibility and costs. Paediatr Anaesth. 2014;24(7):774‐780.
61.
PietersBJConleyLWeifordJHamiltonMWicklundBBooserAStrikerAWhitneySSinghalV. Prophylactic versus reactive transfusion of thawed plasma in patients undergoing surgical repair of craniosynostosis: a randomized clinical trial. Paediatr Anaesth. 2015;25(3):279‐287.
62.
MogensenSLubenowNNilssonP, et al.An evaluation of the mixed pediatric unit for blood loss replacement in pediatric craniofacial surgery. Paediatr Anaesth. 2017;27(7):711‐717.
63.
KurnikNMBristolRManeriCSinghalRSinghDJ. Open craniosynostosis surgery: effect of early intraoperative blood transfusion on postoperative course. J Craniofac Surg. 2017;28(5):e505‐e510.
64.
MuhlyWTTanJMHsuG, et al.Care standardization reduces blood donor exposures and transfusion in complex cranial vault reconstruction. Hosp Pediatr. 2018;8(10):595‐603.
65.
EscherPJTuAKearneyS, et al.Minimizing transfusion in sagittal craniosynostosis surgery: the children’s hospital of minnesota protocol. Childs Nerv Syst. 2019;35(8):1357‐1362.
KnackstedtRPatelN. Enhanced recovery protocol after fronto-orbital advancement reduces transfusions, narcotic usage, and length of stay. Plast Reconstr Surg Glob Open. 2020;8(10):e3205.
68.
KurlanderDEAschaMMarshallDC, et al.Impact of multidisciplinary engagement in a quality improvement blood conservation protocol for craniosynostosis. J Neurosurg Pediatr. 2020;26(4):406‐414. Published online June 12, 2020:1–9.
69.
BeetheABSpitznagelRAKuglerJA, et al.The road to transfusion-free craniosynostosis repair in children less than 24 months old: a quality improvement initiative. Pediatr Qual Saf. 2020;5(4):e331.
70.
EscherPJTuADKearneySL, et al.A protocol of situation-dependent transfusion, erythropoietin and tranexamic acid reduces transfusion in fronto-orbital advancement for metopic and coronal craniosynostosis. Childs Nerv Syst. 2021;37(1):269‐276.
71.
VegaRALyonCKierceJFTyeGWRitterAMRhodesJL. Minimizing transfusion requirements for children undergoing craniosynostosis repair: the CHoR protocol. J Neurosurg Pediatr. 2014;14(2):190‐195.
72.
VelardiFDi ChiricoADi RoccoC, et al. “No allogeneic blood transfusion” protocol for the surgical correction of craniosynostoses. II. Clinical application. Childs Nerv Syst. 1998;14(12):732‐739; discussion 740–1.
73.
NaranSCladisFFearonJ, et al.Safety of preoperative erythropoietin in surgical calvarial remodeling: an 8-year retrospective review and analysis. Plast Reconstr Surg. 2012;130(2):305e‐310e.
74.
FeldmanJMRothJVBjorakerDG. Maximum blood savings by acute normovolemic hemodilution. Anesth Analg. 1995;80(1):108‐113.
75.
CarlessPAHenryDAMoxeyAJ, et al.Cell salvage for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2010;3:CD001888.
76.
CarrierMDenaultALavoieJPerraultLP. Randomized controlled trial of pericardial blood processing with a cell-saving device on neurologic markers in elderly patients undergoing coronary artery bypass graft surgery. Ann Thorac Surg. 2006;82(1):51‐55.
77.
McCormackPL. Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis. Drugs. 2012;72(5):585‐617.
78.
SlaughterTFGreenbergCS. Antifibrinolytic drugs and perioperative hemostasis. Am J Hematol. 1997;56(1):32‐36.
79.
DunnCJGoaKL. Tranexamic acid: a review of its use in surgery and other indications. Drugs. 1999;57(6):1005‐1032.
80.
FaensenBHainCHöhneJSchwabePHaasNSchmidmaierGWildemannB. Aprotinin application has no negative effect on osseous implant integration: a biomechanical and histomorphometric investigation in a rat model. Arch Orthop Trauma Surg. 2009;129(1):51‐56.
81.
HenryDCarlessPFergussonDLaupacisA. The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis. CMAJ. 2009;180(2):183‐193.
82.
HenryDACarlessPAMoxeyAJO'ConnellDStokesBJMcClellandBLaupacisAFergussonD. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2001;1:CD001886.
83.
WilderNSKavaranaMNVoepel-LewisT, et al.Efficacy and safety of aprotinin in neonatal congenital heart operations. Ann Thorac Surg. 2011;92(3):958‐963.
84.
ChauhanSBisoiAKumarN, et al.Dose comparison of tranexamic acid in pediatric cardiac surgery. Asian Cardiovasc Thorac Ann. 2004;12(2):121‐124.
85.
BreuerTMartinKWilhelmM. et al.The blood sparing effect and the safety of aprotinin compared to tranexamic acid in paediatric cardiac surgery. Eur J Cardiothorac Surg. 2009;35(1):167‐171. author reply 171.
86.
DietrichWSpäthPEbellARichterJA. Prevalence of anaphylactic reactions to aprotinin: analysis of two hundred forty-eight reexposures to aprotinin in heart operations. J Thorac Cardiovasc Surg. 1997;113(1):194‐201.
87.
NapierJABruceMChapmanJ, et al.Guidelines for autologous transfusion. II. Perioperative haemodilution and cell salvage. British Committee for Standards in Haematology Blood Transfusion Task Force. Autologous Transfusion Working Party. Br J Anaesth. 1997;78(6):768‐771.
88.
DiazJHLockhartCH. Hypotensive anaesthesia for craniectomy in infancy. Br J Anaesth. 1979;51(3):233‐235.
89.
FaughtCWellsPFergussonDLaupacisA. Adverse effects of methods for minimizing perioperative allogeneic transfusion: a critical review of the literature. Transfus Med Rev. 1998;12(3):206‐225.
90.
CarlessPAAnthonyDMHenryDA. Systematic review of the use of fibrin sealant to minimize perioperative allogeneic blood transfusion. Br J Surg. 2002;89(6):695‐703.
91.
KerKRobertsI. Tranexamic acid for surgical bleeding. Br Med J.2014;349:g4934.
92.
FurtmullerRSchlagMGBergerMHopfRHuckSSieghartWRedlH. Tranexamic acid, a widely used antifibrinolytic agent, causes convulsions by a gamma-aminobutyric acid(A) receptor antagonistic effect. J Pharmacol Exp Ther. 2002;301(1):168‐173.
93.
LeckerI, 94 - Lecker I, Wang D-S, Whissell PD, Avramescu S, Mazer CD and Orser BA 95 - Carson JL, Stanworth SJ, Roubinian N, Fergusson DA, Triulzi D, Doree C and Hebert PC. Tranexamic acid concentrations associated with human seizures inhibit glycine receptors. J Clin Invest. 2012;122(12):4654‐4666.
94.
LeckerIWangD-SWhissellPDAvramescuSMazerCDOrserBA. Tranexamic acid-associated seizures: causes and treatment. Ann Neurol. 2016;79(1):18‐26.
95.
CarsonJLStanworthSJRoubinianNFergussonDATriulziDDoreeCHebertPC. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev. 2016;10:CD002042.
